RESEARCH-USE BIOSIMILAR ANTIBODY
Moxetumomab
Antibody fusion protein · Not specified
Moxetumomab is a CD22-targeting monoclonal antibody that forms the component of Moxetumomab Pasudotox, a recombinant CD22-targeting immunotoxin. Moxetumomab binds to CD22 on malignant B cells and delivers the PE38 toxin domain to tumor cells. Moxetumomab can be used in research on relapsed or refractory hairy cell leukemia.
PRODUCT OVERVIEW
A research-use configuration for comparative antibody studies
Moxetumomab is a CD22-targeting monoclonal antibody that forms the component of Moxetumomab Pasudotox, a recombinant CD22-targeting immunotoxin. Moxetumomab binds to CD22 on malignant B cells and delivers the PE38 toxin domain to tumor cells. Moxetumomab can be used in research on relapsed or refractory hairy cell leukemia.
Moxetumomab is a recombinant research-use antibody directed against SIGLEC2.